Biogen (NASDAQ:BIIB) Sets New 1-Year High – Should You Buy?

Biogen Inc. (NASDAQ:BIIB)’s stock price hit a new 52-week high during trading on Tuesday . The company traded as high as $226.43 and last traded at $224.87, with a volume of 262187 shares traded. The stock had previously closed at $219.07.

Analysts Set New Price Targets

A number of equities analysts have weighed in on BIIB shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biogen in a research note on Monday, June 22nd. Bank of America decreased their price target on shares of Biogen from $217.00 to $215.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 21st. Needham & Company LLC boosted their price objective on shares of Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. TD Cowen upped their price objective on Biogen from $215.00 to $225.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $300.00 price objective on shares of Biogen in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $230.14.

Biogen Stock Up 2.7%

The company has a market cap of $33.23 billion, a P/E ratio of 39.81, a price-to-earnings-growth ratio of 2.38 and a beta of 0.17. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The firm’s 50 day moving average price is $211.20 and its 200-day moving average price is $198.54.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same period in the previous year, the firm posted $5.47 earnings per share. Biogen’s revenue for the quarter was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities research analysts expect that Biogen Inc. will post 12.41 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Rothschild Investment LLC raised its holdings in Biogen by 12.3% in the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 56 shares during the period. Wedbush Securities Inc. grew its holdings in shares of Biogen by 5.1% in the 2nd quarter. Wedbush Securities Inc. now owns 1,164 shares of the biotechnology company’s stock valued at $251,000 after buying an additional 56 shares during the period. Meeder Advisory Services Inc. increased its position in shares of Biogen by 1.2% in the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock valued at $866,000 after buying an additional 57 shares in the last quarter. Kera Capital Partners Inc. increased its position in shares of Biogen by 3.5% in the 1st quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock valued at $316,000 after buying an additional 58 shares in the last quarter. Finally, Parallel Advisors LLC raised its stake in Biogen by 1.5% during the 1st quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after buying an additional 65 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Company Profile

Biogen Inc is a biotechnology company focused on discovering, developing and commercializing therapies for neurological and neurodegenerative diseases. Founded in 1978, the company is headquartered in Cambridge, Massachusetts, and serves patients and healthcare providers in markets around the world.

Biogen’s portfolio includes treatments for multiple sclerosis, including Tecfidera, Vumerity, Tysabri, Avonex and Plegridy, as well as Spinraza for spinal muscular atrophy, developed in collaboration with Ionis Pharmaceuticals.